Nifty, Sensex Remain Weak– Tuesday Closing Report
Moneylife Digital Team 24 May 2022
We had mentioned in Monday’s closing report that Nifty and Sensex unimpressed by inflation-control measures. On Tuesday, the indices opened flat and ended with loss. On the National Stock Exchange (NSE), 549 stocks advanced, 1,528 declined, and 50 remained unchanged with advance decline ratio of 0.36. 
 
The trend of the major indices on Tuesday’s trading are given in the table below:
 
 
Nifty, Sensex were volatile during the day, declined in the first session then touched opening level and fell severely in the afternoon to close in red. Sector wise Nifty Media and Nifty IT were the biggest losers whereas Nifty Financial Services and Nifty Bank were the biggest gainers. The broader market indices underperformed their larger peers with BSE Midcap and BSE Small cap closing 0.85% and 1.14% down respectively.
 
Balrampur Chini’s Q4FY21-22 revenue grew by 25.5% to Rs 1,279 crore and the profit grew by 2.1% to Rs 240.5 crore on a y-o-y basis. Bank of India’s Q4FY21-22 net interest income grew by 35.77% to Rs 3,986 crore and the net profit grew by 142% to Rs 606 crore on a y-o-y basis. The board has recommended a dividend of Rs 2 per share. GIC Singapore will invest Rs 2,195 crore in Aditya Birla Fashion and Retail for approx. 7.5% equity stake in the company. Grasim’s Q4FY21-22 revenue grew by 45% to Rs 6,376 crore and the profit grew by 75.7% to Rs 813.5 crore on a y-o-y basis.
 
Gujarat Alkalies Q4FY21-22 revenue grew by 70% to Rs 1,141 crore and its net profit was up multifold to Rs 220.7 crore as compared to Rs 34 crore on a y-o-y basis. Jyothy Labs Q4FY21-22 revenue grew by 10.4% to Rs 546 crore and the net profit grew by 29% to Rs 38 crore on a y-o-y basis. NIIT’s Q4FY21-22 revenue grew by 34.4% to Rs 375 crore and the profit grew by 44.7% to Rs 67 crore on a y-o-y basis.
 
Birlasoft’s Q4FY21-22 revenue was up 22% to Rs 1,101 crore and the profit rose y 34% to Rs 133 on a y-o-y basis. It has announced a buyback of up to 2.79% shares at a price of Rs 500 per share for an amount of up to Rs390 crore.
 
Delhivery IPO listed at Rs 495.20 as compared to its issue price of Rs 487 per share getting a premium of just 1.68% to the issue price. Alembic Pharma has received USFDA approval to market Pirfenidone tablets.
 
The top gainers and top losers of the major indices are given in the table below:
 
 
The closing values of the major Asian indices are given in the table below:
 
 
Comments
IPO Review: Aether Industries Ltd
Moneylife Digital Team 24 May 2022
Aether Industries Ltd (AIL) is a specialty chemicals manufacturer and has eight chemistry competencies including Grignard reaction, organolithium and other organometallic chemistry, ethylene oxide and isobutylene chemistry,...
Balaji Amines: March ’22 Results Update
Moneylife Digital Team 24 May 2022
In Q4FY21-22, Balaji Amines Ltd (BAL) reported stellar set of numbers with revenue growth of 88% y-o-y (year-on-year) and 38% sequentially to Rs779 crore. This was backed by strong volume growth of 18% y-o-y and 22% q-o-q...
Ami Organics: March ’22 Results Update
Moneylife Digital Team 23 May 2022
In Q4FY21-22, Ami Organics’ (Ami) revenue grew by 55% y-o-y (year-on-year) to Rs144 crore, driven by volume and value gains. Volume grew by 23% y-o-y. Sequentially, sales growth was subdued due to logistical challenges and lack of...
Neogen Chemicals: March ’22 Results Update
Moneylife Digital Team 23 May 2022
As anticipated by the management, Neogen Chemicals (Neogen) crossed the Rs450 crore top-line mark in FY21-22. In Q4FY21-22, revenue surged by 69% y-o-y (year-on-year) and 18% q-o-q (quarter-on-quarter) to Rs157 crore, driven by...
Free Helpline
Legal Credit
Feedback